Bronchoalveolar Cell Lung Cancer Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028477 (Bronchoalveolar Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00368992S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung CancerTreatment